benzyl N-(C-methyl-N-phenylmethoxycarbonylcarbonimidoyl)carbamate | 167780-26-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl N-(C-methyl-N-phenylmethoxycarbonylcarbonimidoyl)carbamate
• CAS: 167780-26-9
• 化学式: C₁₈H₁₈N₂O₄
• 分子量: 326.352
• InChiKey: VBAFKOVJCGBYBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl N-(C-methyl-N-phenylmethoxycarbonylcarbonimidoyl)carbamate 以83%的产率得到
  参考文献：
  名称：

  Eustache J., Grob A., Tetrahedron Lett., 36 (1995) N 12, S 2045-2046

  摘要：

  DOI：
• 作为产物：
  描述：

  氯甲酸苄酯 、 N-(benzyloxycarbonyl)acetamidine 以 二氯甲烷 为溶剂， 以36%的产率得到benzyl N-(C-methyl-N-phenylmethoxycarbonylcarbonimidoyl)carbamate
  参考文献：
  名称：

  N，N'-双（苄氧基羰基）乙am，一种用于将胺和醇转化为乙am的通用试剂

  摘要：

  N，N′-双（苄氧基羰基）乙am是一类新的通用试剂的原型，用于将胺和醇转化为取代的idine。描述了1的制备及其潜在用途。

  DOI：

  10.1016/0040-4039(95)00185-f

文献信息

• Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases
  申请人：Betschart Claudia

  公开号：US20090054467A1

  公开（公告）日：2009-02-26

  The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.

  本发明提供了公式I的化合物，或其药理学上可接受的盐或酯，其中符号具有定义的含义，这些化合物是卡特普西林K的抑制剂，并在药学上用于治疗与卡特普西林K有关的疾病和医疗条件，例如各种疾病，包括炎症，类风湿性关节炎，骨关节炎，骨质疏松和肿瘤。
• Eustache J., Grob A., Tetrahedron Lett., 36 (1995) N 12, S 2045-2046
  作者：Eustache J., Grob A.

  DOI：——

  日期：——
• Conformationally constrained no synthase inhibitors: Rigid analogs of L-N-iminoethylornithine
  作者：Jacques Eustache、Alfred Grob、Charles Lam、Odile Sellier、Gerhard Schulz

  DOI：10.1016/s0960-894x(98)00532-0

  日期：1998.11

  The synthesis of eight rigid analogs of L-N-iminoethylornithine (L-NIO) is described. The compounds have been evaluated for their inhibition of inducible nitric oxide synthase. Preliminary structure-activity relationships are discussed. (C) 1998 Elsevier Science Ltd. All rights reserved.
• SYNTHESIS OF BICYCLIC COMPOUNDS AND METHOD FOR THEIR USE AS THERAPEUTIC AGENTS
  申请人：Wulff Jeremy E.

  公开号：US20130210904A1

  公开（公告）日：2013-08-15

  Disclosed embodiments concern the synthesis and use of therapeutic compounds that for treating emerging flu strains and minimizing resistance to such strains. Methods for making the disclosed compounds concern using a base-mediated addition/cyclization sequence followed by functional group manipulation to develop functionalized compounds that can target neuraminidase, which makes them ideal candidates for treating influenza. Pharmaceutical compositions comprising the therapeutic compounds and biologically-acceptable materials are also described. Methods of inhibiting neuraminidase in subjects that are suspected of containing neuraminidase are also described. The use of metabolites of the disclosed compounds can also be used in diagnostic assays for therapeutic dosing of the disclosed compounds.
• US7452886B2
  申请人：——

  公开号：US7452886B2

  公开（公告）日：2008-11-18